13-OAHSA
Based on 1 Customer Validation
13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.00%
- CAS. Nr.: 1997286-67-5
- Formel: C36H68O4
- Molecular Weight:564.92
-
Speicherung:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-W709961
5-OAHSAEndogenous Metabolite -
HY-113878
12-OAHSAAnti-Obese Agent -
HY-131934
9-OAHSAAnti-Inflammatory reagent -
HY-116193
5-PAHSAAnti-Inflammatory Agent -
HY-117586
9-PAHPAAntidiabetic/Anti-inflammatory Agent -
HY-131668
9-POHSAAnti-Inflammatory Agent -
HY-138177
Butyryl-Coenzyme A sodiumButyric Acid Derivative -
HY-158583
13-POHSAFAHFA -
HY-130434
12-SAHSAFAHFA -
HY-116193R
5-PAHSA (Standard)Anti-Inflammatory Agent -
HY-130352
9-SAHSAFAHFA -
HY-133851
10-PAHSAFatty Ester
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
Human Endogenous Metabolite |
Chemical Information
-
CAS. Nr. 1997286-67-5
-
Appearance Liquid
-
Molecular Weight 564.92
-
Formel C36H68O4
-
Color Colorless to light yellow
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(OC(CCCCC)CCCCCCCCCCCC(O)=O)=O
-
Synonyms
9Z-Octadecenoic acid, 12-carboxy-1-pentyldodecyl ester
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Solution, -20°C, 2 years
Protokoll
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Human Islet Cell Culture
The method of preserving islets in vitro, with purified reduced immunogenicity. The steps are islet isolation, islet cell purification, in vitro determination of islet function and islet cell culture.
Reinheit & Dokumentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
13-OAHSA Related Classifications
HY-158584 Related Classifications
Powered by Bioz